TABLE 2.
Characteristics of seropositive patients with regard to development of neutralizing antibody capacity
| Parameter | NTs (N = 38) | No NTs (N = 18) |
|---|---|---|
| Age, y | 59 (56–63) | 66 (60–72) |
| M:F | 1:0.6 | 1:0.6 |
| Time after transplantation, mo | 150 (94–229) | 149 (108–214) |
| Creatinine, mg/dl | 1.4 (1.0–1.9) | 1.7 (1.3–2.0) |
| eGFR, ml/min/1.73 m2 | 49 (35–75) | 36 (29–50) |
| IgG antibody titer, BAU/ml | 384 (169–749) | 56 (46–220)** |
| Immunosuppression | ||
| CNI | 37 (97.4%) | 17 (94.4%) |
| Steroids | 33 (86.8%) | 18 (100%) |
| mTOR inhibitor | 2 (5.3%) | 2 (11.1%) |
| Azathioprine | 2 (5.3%) | 0 (0%) |
| MMF | 18 (47.4%) | 8 (44.4%) |
| ≤1 g/d | 16 (88.9%) | 7 (87.5%) |
| ≥1 g/d | 2 (11.1%) | 1 (12.5%) |
| Dual therapy | 17 (44.7%) | 9 (50%) |
| With MMF | 3 (17.6%) | 0 (0%) |
| No MMF | 14 (82.4%) | 9 (100%) |
| Triple therapy | 19 (50%) | 9 (50%) |
| With MMF | 15 (78.9%) | 8 (88.9%) |
| No MMF | 4 (21.1%) | 1 (11.1%) |
| Monotherapy | 2 (5.3%) | 0 (0%) |
Note: Dichotomo
Abbreviations: CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; NT, neutralizing antibody capacity.
***
Represent significant difference between the groups (p < .001) using Mann Whitney test.